Skip to main content Skip to search Skip to main navigation

IPEC: Position Paper on Nitrosamine Risks in Excipients

The IPEC (International Pharmaceutical Excipients Council Federation) has published a summarizing position paper on "The Role of Excipients in Determining N-Nitrosamine Risks for Drug Products". The 7-page paper describes the IPEC Federation’s position on the role of excipients when conducting N-nitrosamine risk assessments for medicinal products.

According to the IPEC, the issue for the paper is that the presence of N-nitrosamines in drug products continues to be a global concern. Excipients are considered as a potential risk factor during the drug product risk assessment. The focus of this position paper is to expand on the potential contribution excipients may or may not have on the formation of nitrosamines in final drug products. The presence of nitrites and vulnerable amines in excipients are also considered.

Even though excipient manufacturers are under no specific regulatory requirement to provide risk assessments on nitrosamines to regulatory agencies, the IPEC considers a risk-based cooperation between the pharmaceutical manufacturer and an excipient supplier appropriate. It is necessarily in the interest of an excipient manufacturer to supply safe excipients. Water in various qualities, raw materials, and excipient processing conditions could be sources of nitrites and nitrates. Excipient suppliers should carefully evaluate the potential risk related to their excipients. This will assist medicinal product manufacturers to fulfill their regulatory obligation which is to conduct risk assessments for their drug products.


Source:

IPEC: The Role of Excipients in Determining N-Nitrosamine Risks for Drug Products

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Applying the FDA’s 7-Step Model for AI/ML Validation in GMP Environments: One Year Later

Artificial intelligence is becoming increasingly important in GMP-regulated environments, presenting companies with new regulatory challenges. This article summarizes the latest regulatory developments, introduces a validation framework based on the FDA's seven-step model, and outlines initial practical experience with AI/ML validation.

Read more
What are the General Requirements for Standard Documents?

What are the General Requirements for Standard Documents?

Here's the answer:
Read more
EDQM: Revised Guidance on Sister File Applications

EDQM: Revised Guidance on Sister File Applications

The European Directorate for the Quality of Medicines & HealthCare (EDQM) has revised its Guidance on applications for “sister files” (PA/PH/CEP (09) 141). The revision is intended to support consistent application of the procedure and provide greater clarity on the classification and assessment of the corresponding CEP applications.
Read more
Swissmedic Clarifies Requirements for QR Codes on Medicinal Product Packaging

Swissmedic Clarifies Requirements for QR Codes on Medicinal Product Packaging

Swissmedic has revised its guidance document “Mobile technologies” and added two new entries to the related questions and answers. The update follows an increasing number of queries regarding the details and placement of URLs, the positioning of QR codes and their captions.
Read more
EMA: Withdrawal of an Application due to Missing Confirmation of a Manufacturing Site’s GMP Status

EMA: Withdrawal of an Application due to Missing Confirmation of a Manufacturing Site’s GMP Status

EMA reported that Scholar Rock Netherlands withdrew its application for Isembyld after evaluation had progressed through the final round of questions. EMA’s provisional view was that the medicine could not be authorised because the applicant had not provided confirmation that the manufacturing site complied with EU GMP requirements.

Read more
France: ANSM Launches Pilot Project to Extend the Shelf Life of Medicines

France: ANSM Launches Pilot Project to Extend the Shelf Life of Medicines

The French medicines agency ANSM has published an update on its “Longue vie aux médicaments” pilot project aimed at extending the shelf life of medicines. Fourteen pharmaceutical companies responded to the call for applications. The project covers a total of 73 medicines, including commonly used products containing paracetamol, levothyroxine, melatonin or lithium.
Read more
Previous
Next